Long term follow-up of "full metal jacket" of de novo coronary lesions with new generation Zotarolimus-eluting stents. (15th October 2016)

• Record Type: Journal Article
• Authors: Durante, Alessandro; Foglia Manzillo, Giovanni; Burzotta, Francesco; Trani, Carlo; Aurigemma, Cristina; Summaria, Francesco; Patrizi, Roberto; Talarico, Giovanni Paolo; Latib, Azeem; Figini, Filippo; Romagnoli, Enrico; De Vita, Mariarosaria; Fantoni, Cecilia; My, Luigi; Larosa, Claudio; Manzoli, Alessandro; Turturo, Maurizio; Berni, Andrea; Corrado, Giovanni
• Is Part Of: International journal of cardiology. Volume 221(2016)
• Page Start: 1008
• Page End: 1012
• Publication Date: 2016-10-15
• Subjects: DES -- Drug eluting stent -- PCI -- Full metal jacket -- ZES; Cardiology -- Periodicals; Electronic journals; 616.12
• DOI: 10.1016/j.ijcard.2016.07.050
• Languages: English
• ISSNs: 0167-5273

Abstract

Abstract: Background: Diffuse coronary artery disease treatment still remains a challenge for interventional cardiologists and cardiac surgeons. There are few data on full metal jacket (FMJ) stenting, especially with new-generation drug-eluting stents. We aimed to assess the efficacy and safety of FMJ with new-generation Zotarolimus-eluting stents (n-ZES). Methods and results: All patients who underwent FMJ with n-ZES (≥ 60 mm stent length) in eleven Italian interventional centers participating in the Clinical Service® project were included in this analysis. The project population consisted of 120 patients and 122 lesions. Mean age was 67 ± 10 years and 95 (79.2%) patients were male. A chronic total occlusion was present in 34 lesions (27.9%). The number of stents implanted per lesion was 2.9 ± 0.8, and the diameter of the stents was 3.0 ± 0.5 mm. Predilation and post-dilatation were performed in 107 (87.7%) and 92 (75.4%) patients, respectively. At 41 ± 21 month follow-up there were 2 patients with subacute definite stent thrombosis, 6 patients (5.0%) had cardiac death and 5 patients (4.2%) had non-fatal myocardial infarction. Seven patients (5.8%) underwent clinically-driven target lesion revascularization. Fourteen patients (11.7%) had at least one major adverse cardiac event. Conclusion: The treatment of diffuse coronary artery disease with FMJ stenting with n-ZES appears to be effective and safe. Late and very-late ST does not seem to be an issue and the rate of restenosis and of major cardiac adverse events after more than 3-year follow-up is rather low.